Source link : https://newshealth.biz/health-news/drug-combo-outpaces-standard-chemo-in-r-r-lbcl/
A combo of the novel bispecific antibody mosunetuzumab and the antibody-drug conjugate polatuzumab vedotin (Mosun-Pola) significantly outperformed standard chemotherapy in transplant-ineligible patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), an industry-funded phase 3 trial found. Over a median 23.2 months follow-up, progression-free survival in patients with R/R LBCL was a median of 11.5 […]
The post Drug Combo Outpaces Standard Chemo in R/R LBCL first appeared on News Health.
—-
Author : News Health
Publish date : 2025-07-09 05:33:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8